September 28, 2015.
The industry’s Oscars, the Prix Galien USA Awards will bring red carpet glamor and, hopefully, some cheer to the industry this fall.
The Prix Galien forum and awards will once again convene some of the industry’s biggest personalities for a day of accolades and introspection on October 27th. In a season full of negativity and criticism, the industry will pause to honor some of its top achievements before bracing itself for a combative political year.
“At a time when pharma’s reputation is questioned relentlessly, Prix Galien is among the few independent forums that indicates the importance of scientific innovation and its value for greater human health,” said Gil Bashe, managing partner, health at Finn Partners, and a member of the Galien Foundation advisory board. “Operating as a non-governmental body with independent judging, a Prix Galien nomination and award represents the aspiration of industry scientists to conquer disease and return people to healthier life,” he added.
Prix Galien USA assembles 500 attendees each year bringing together academic researchers, industry, patient organizations and more. Government, the regulatory community and international organizations are represented in force, according to the foundation.
The forum, held at New York’s Alexandria Center for Life Sciences, offers a full slate of discussion from with top scientists and industry researchers who review the most significant challenges in the global burden of disease and highlight the latest research and clinical pathways toward diagnosis, treatment and cure. But don’t expect a day without controversy. Sparks flew last year, and are likely to again given the industry’s current environment.
The Forum’s 10 member Advisory Committee, including four Nobel Prize laureates, has selected a keynote luncheon speaker and eight expert panels to advance this year’s Forum theme of “Next Wave Treatments for Unmet Medical Needs”. See the day’s agenda here.
The evening promises slightly more glitz underneath the giant blue whale at the American Museum of Natural History with awards given for the industry’s pharmaceutical, biotechnology and medical technology products of the year. It’s an honor just to be nominated, but we know everyone wants that prize… the list of nominees.
Who do you think will win? Follow and engage on Twitter at @GalienFdn, as well as Facebook, LinkedIn and YouTube.
@PharmExecutive will also keep the Twitter conversation going at #PrixGalien.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.